Adam Sherwat, director of the Office of Infectious Diseases at the FDA's Center for Drug Evaluation and Research, is leaving the agency. This office falls under CDER, which oversees most prescription drugs in the US. Sherwat had served as director since May 2025 and previously as deputy director since September 2020. His departure is part of a broader trend of high-ranking FDA officials leaving in the past year. The agency faces challenges such as the loss of approximately 20% of staff since the beginning of the year and frequent changes in CDER leadership – four directors in one year. These changes raise concerns about continuity in drug review, including oncology, neurology and rare diseases. The FDA has announced that it will provide additional information on succession.[1][2][3][4]